BioCentury | Jan 18, 2017
Clinical News

VivaGel BV regulatory update

...FDA granted Qualified Infectious Disease Product (QIDP) and Fast Track designations to VivaGel BV astodrimer sodium from Starpharma...
...Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia Product: VivaGel BV astodrimer sodium (SPL7013) Business: Infectious Nora Weintraub astodrimer sodium SPL7013 Starpharma Holdings Ltd. VivaGel BV...
BioCentury | Sep 28, 2015
Clinical News

VivaGel astodrimer sodium regulatory update

...The European Commission approved an MAA from Starpharma for VivaGel BV astrodrimer sodium to treat bacterial vaginosis...
...testing to treat recurrent BV. Starpharma Holdings Ltd. (ASX:SPL), Melbourne, Australia Product: VivaGel astodrimer sodium ( SPL7013...
BioCentury | Jul 28, 2014
Clinical News

VivaGel astodrimer sodium: SPA received

...FDA for a pair of identical, double-blind, placebo-controlled, international Phase III trials to evaluate 1% VivaGel...
...said it plans to start the trials in the next month. Starpharma is also developing VivaGel...
...planned for this half. Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia Product: VivaGel astodrimer sodium ( SPL7013...
BioCentury | Aug 22, 2011
Clinical News

VivaGel: Phase II start

...Starpharma will begin a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 1% and 3% VivaGel...
...history of recurrent bacterial vaginosis. Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia Product: VivaGel ( SPL7013...
BioCentury | May 30, 2011
Clinical News

VivaGel: Phase II data

...U.S. Phase II trial in 132 patients showed that once-daily 0.5%, 1% and 3% topical VivaGel...
...and odor was shorter for VivaGel compared to placebo. Furthermore, 83% of patients receiving 1% VivaGel...
...placebo. VivaGel was well tolerated. Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia Product: VivaGel ( SPL7013...
BioCentury | Aug 23, 2010
Clinical News

VivaGel: Phase II started

...began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 0.5%, 1% and 3% topical VivaGel...
...7 days in 132 patients. Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia Product: VivaGel ( SPL7013...
BioCentury | Jul 26, 2010
Clinical News

VivaGel: Phase II start

...7 days in 132 patients. Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia Product: VivaGel ( SPL7013...
BioCentury | Nov 19, 2009
Financial News

Starpharma raises A$15.6 million

...Corporate Finance managed the placement. Starpharma plans to use the funds for clinical trials of VivaGel...
BioCentury | Aug 10, 2009
Clinical News

VivaGel: Feasibility study data

...VivaGel completely inhibited HIV and HSV-2 infection ex vivo. At 1 and 3 hours post-administration, VivaGel's...
...retained in all women for both viruses. At 12 and 24 hours post-administration, >90% of VivaGel's...
...with no serious adverse events. Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia Product: VivaGel ( SPL7013...
BioCentury | Dec 8, 2008
Clinical News

Starpharma preclinical data

...In vitro, SPL7013 inhibited HPV types 16, 18 and 31, which are associated with cervical cancer...
...6 and 11, which are associated with genital warts. SPL7013 is the active ingredient in VivaGel...
...genital herpes and HIV/AIDS transmission. Starpharma Holdings Ltd. (ASX:SPL; Pink:SPHRY), Melbourne, Australia Product: VivaGel ( SPL7013...
Items per page:
1 - 10 of 28